Psilocybin, a compound which has shown promise in counteracting treatment-resistant depression, leads the charge in helping JUUL users and smokers alike quit for good, according to a paper from Johns Hopkins University.
-
-
We downloaded RLOVE, a dating app for psychonauts and “light warriors.” Here’s what happened
RLOVE is a new dating app designed “to connect awakened souls” who aren’t able to find partners through more traditional, tried and true means such as OkCupid.
-
MindMed, owners of addiction-treating 18-MC, and Broadway Gold (BRD.V) announce definite arrangement for RTO
MindMed, owners of the iboga-related 18-MC drug, is going public after firming up its reverse take-over of Broadway Gold Mining (BRD.V).
-
Why DARPA is reviving psychedelics research for the U.S. military in the shadow of MK-Ultra
On the 18-year anniversary of September 11, DARPA, the U.S. military research arm, said it was pursuing the development of fast-acting drugs to treat “chronic depression and post-traumatic stress.”
-
Orthogonal Thinker closes $2.5M bridge financing to fund development of proprietary psilocybin drug
Orthogonal Thinker, a biotech holding company with the aim of bringing psilocybin to the world for $1 a dose, recently announced the closing of $2.5M raised in bridge financing.
